Skip to content

Study · Randomized controlled trial · 2020

5 results

ACTH Infusion Impairs Baroreflex Sensitivity-Implications for Cardiovascular Hypoglycemia-Associated Autonomic Failure.

Leung JH, Bayomy OF, Bonyhay I, Celli J, White J, Freeman R, Adler GK

The Journal of clinical endocrinology and metabolism1 Jul 2020Cited by 3 (Europe PMC)

PMID32353115 (opens in a new tab)PMCIDPMC7255850 (opens in a new tab)DOI10.1210/clinem/dgaa221 (opens in a new tab)PepBankPUB-32353115
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialActivity measurement

    In healthy adults, cosyntropin lowered baroreflex sensitivity during infusion versus placebo (14.4 ± 1.43 versus 17.3 ± 1.65 mm Hg/ms).

    In plain wordsIn healthy adults, cosyntropin lowered baroreflex sensitivity during infusion compared with placebo.

    Peptide
    Cosyntropin
    Outcome
    DecreaseBaroreflex sensitivity during infusion versus placebo
    Study

    n: not reported in source

    Comparator
    Normal saline placebo
    Outcome group
    Cardiovascular Autonomic Function · Cardiovascular
    Studied dose
    70 μg/hour · intravenous infusion · 2.5 hours in the morning and again in the early afternoonAs given in this study (human).

    Measurements

    Baroreflex sensitivity, baseline
    17.8 mm Hg/ms
    cosyntropin, ±1.38 as reported
    Baroreflex sensitivity, baseline
    17 mm Hg/ms
    placebo, ±2.07 as reported
    Baroreflex sensitivity, during infusion
    14.4 mm Hg/ms
    cosyntropin, ±1.43 as reported
    Baroreflex sensitivity, during infusion
    17.3 mm Hg/ms
    placebo, ±1.65 as reported

    Source sentences

    Summary
    Cosyntropin infusion attenuated BRS (mm Hg/ms) as compared to placebo (baseline 17.8 ± 1.38 vs 17.0 ± 2.07; during 14.4 ± 1.43 vs 17.3 ± 1.65; and next day 14.8 ± 1.42 vs 18.9 ± 2.04; P < .05, time by treatment, analysis of variance).
    3 context sentences
    Summary · context
    A double-blind, placebo-controlled, random-order, cross-over study was conducted.
    Summary · context
    Participants included healthy men and women.
    Summary · context
    Interventions included an intravenous infusion of cosyntropin (70 μg/hour for 2.5 hours in the morning and again in the early afternoon) vs normal saline placebo.
  2. 02HumanRandomized controlled trialActivity measurement

    In healthy adults, cosyntropin lowered next-day baroreflex sensitivity versus placebo (14.8 ± 1.42 versus 18.9 ± 2.04 mm Hg/ms).

    In plain wordsIn healthy adults, cosyntropin lowered next-day baroreflex sensitivity compared with placebo.

    Peptide
    Cosyntropin
    Outcome
    DecreaseBaroreflex sensitivity next day versus placebo
    Study

    n: not reported in source

    Comparator
    Normal saline placebo
    Outcome group
    Cardiovascular Autonomic Function · Cardiovascular
    Studied dose
    70 μg/hour · intravenous infusion · 2.5 hours in the morning and again in the early afternoonAs given in this study (human).

    Measurements

    Baroreflex sensitivity, next day
    14.8 mm Hg/ms
    cosyntropin, ±1.42 as reported
    Baroreflex sensitivity, next day
    18.9 mm Hg/ms
    placebo, ±2.04 as reported

    Source sentences

    Summary
    Cosyntropin infusion attenuated BRS (mm Hg/ms) as compared to placebo (baseline 17.8 ± 1.38 vs 17.0 ± 2.07; during 14.4 ± 1.43 vs 17.3 ± 1.65; and next day 14.8 ± 1.42 vs 18.9 ± 2.04; P < .05, time by treatment, analysis of variance).
    3 context sentences
    Summary · context
    A double-blind, placebo-controlled, random-order, cross-over study was conducted.
    Summary · context
    Participants included healthy men and women.
    Summary · context
    Interventions included an intravenous infusion of cosyntropin (70 μg/hour for 2.5 hours in the morning and again in the early afternoon) vs normal saline placebo.
  3. 03HumanNon-randomized trialActivity measurement

    In healthy adults, baroreflex sensitivity decreased during the final 30 minutes of morning cosyntropin infusion versus baseline (P < .01).

    In plain wordsIn healthy adults, baroreflex sensitivity fell during cosyntropin infusion compared with baseline.

    Peptide
    Cosyntropin
    Outcome
    DecreaseBaroreflex sensitivity during infusion versus baseline
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Cardiovascular Autonomic Function · Cardiovascular
    Studied dose
    70 μg/hour · intravenous infusion · 2.5 hours in the morning and again in the early afternoonAs given in this study (human).

    Source sentences

    Summary
    BRS was decreased during the final 30 minutes of the morning cosyntropin infusion as compared to baseline (P < .01) and remained suppressed the next day (16 hours after afternoon infusion) (P < .025).
    3 context sentences
    Summary · context
    A double-blind, placebo-controlled, random-order, cross-over study was conducted.
    Summary · context
    Participants included healthy men and women.
    Summary · context
    Interventions included an intravenous infusion of cosyntropin (70 μg/hour for 2.5 hours in the morning and again in the early afternoon) vs normal saline placebo.
  4. 04HumanNon-randomized trialActivity measurement

    In healthy adults, baroreflex sensitivity remained suppressed 16 hours after afternoon cosyntropin infusion versus baseline (P < .025).

    In plain wordsIn healthy adults, baroreflex sensitivity remained lower the next day compared with baseline after cosyntropin.

    Peptide
    Cosyntropin
    Outcome
    DecreaseBaroreflex sensitivity next day versus baseline
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Cardiovascular Autonomic Function · Cardiovascular
    Studied dose
    70 μg/hour · intravenous infusion · 2.5 hours in the morning and again in the early afternoonAs given in this study (human).

    Source sentences

    Summary
    BRS was decreased during the final 30 minutes of the morning cosyntropin infusion as compared to baseline (P < .01) and remained suppressed the next day (16 hours after afternoon infusion) (P < .025).
    3 context sentences
    Summary · context
    A double-blind, placebo-controlled, random-order, cross-over study was conducted.
    Summary · context
    Participants included healthy men and women.
    Summary · context
    Interventions included an intravenous infusion of cosyntropin (70 μg/hour for 2.5 hours in the morning and again in the early afternoon) vs normal saline placebo.
  5. 05HumanNon-randomized trialActivity measurement

    In healthy adults receiving cosyntropin or placebo infusions, corrected QT interval was not affected.

    In plain wordsIn healthy adults receiving cosyntropin or placebo, corrected QT interval did not change.

    Peptide
    Cosyntropin
    Outcome
    No significant changeCorrected QT interval
    Study

    n: not reported in source

    Outcome group
    Cardiovascular Autonomic Function · Cardiovascular
    Studied dose
    70 μg/hour · intravenous infusion · 2.5 hours in the morning and again in the early afternoonAs given in this study (human).

    Source sentences

    Summary
    Corrected QT interval was not affected.
    3 context sentences
    Summary · context
    A double-blind, placebo-controlled, random-order, cross-over study was conducted.
    Summary · context
    Participants included healthy men and women.
    Summary · context
    Interventions included an intravenous infusion of cosyntropin (70 μg/hour for 2.5 hours in the morning and again in the early afternoon) vs normal saline placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT02339506

Stress and the Nervous System

Brigham and Women's Hospitaln = 23Apr 2015 to Nov 2020

Autonomic Nervous System · Baroreflex · Stress, Physiological

Trial pageClinicalTrials.govUpdated 3 Dec 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.